Anti‐VEGF Therapy for Neovascular AMD and Polypoidal Choroidal Vasculopathy. Issue 6 (November 2017)

• Record Type: Journal Article
• Authors: Cheung, Gemmy Chui Ming; Lai, Timothy Y.Y.; Gomi, Fumi; Ruamviboonsuk, Paisan; Koh, Adrian; Lee, Won Ki
• Is Part Of: Asia-Pacific journal of ophthalmology. Volume 6:Issue 6(2017)
• Publication Date: 2017-11
• Subjects: age‐related macular degeneration -- anti‐VEGF therapy -- polypoidal choroidal vasculopathy; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; Periodicals; 617.7005
• DOI: 10.22608/APO.2017260
• Languages: English
• ISSNs: 0129-1653

Abstract

Abstract : Abstract: : Anti‐vascular endothelial growth factor (anti‐VEGF) therapy has revolutionized the treatment of neovascular age‐related macular degeneration (AMD). This review will summarize the current evidence of anti‐VEGF therapy in neovascular AMD, including subtypes of retinal angiomatous proliferation and polypoidal choroidal vasculopathy (PCV). Importantly, 2 large multicenter randomized clinical trials evaluating the safety and efficacy of anti‐VEGF monotherapy and combination with photodynamic therapy (PDT) have recently reported initial first‐year outcomes. In this review, we summarize the latest updates in the efficacy and safety of anti‐VEGF monotherapy and combination with PDT in common lesion subtypes. Remaining gaps in current understanding are highlighted where further research is needed.